Second, unlike full-length growth hormone, AOD-9604 does not bind to growth hormone receptors present throughout the body
Yu, L., Li, Y., Gris, A
THESE CHEMICALS ARE NOT INTENDED TO BE USED AND SHOULD NOT BE USED IN INAPPROPRIATE APPLICATIONS, SUCH AS, WITHOUT LIMITATION, FOOD ADDITIVES, DRUGS, COSMETICS, HOUSEHOLD CHEMICALS, OR OTHER APPLICATIONS OUTSIDE OF IN-VITRO LABORATORY RESEARCH, PRE-CLINICAL RESEARCH, OR IN LABORATORY CHEMICAL SYNTHESIS OR TESTING OF DIFFERENT MATERIALS
Thus, injections indirectly balance the mood and regulate appetite
Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised: Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome
